



Press Release  
November 5, 2024

## Invitation to Scandion Oncology webcast and conference call November 11, 2024

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, will publish its Q3 2024 interim report on Monday November 11, 2024, before 09:00 CET.

Scandion's Executive Management will host a webcast and conference call the same day at 09:00 CET presenting the results and a company update. At the end of the presentation there will be a Q&A session.

Access to the event can be obtained as follows:

**LIVE access on Monday November 11, 2024, at 09.00 CET:** <https://financialhearings.com/event/48943>

### REPLAY access

Webcast replay will be available at [www.scandiononcology.com](http://www.scandiononcology.com) in the Investors section and at [www.financialhearings.com](http://www.financialhearings.com)

### For further information please contact:

Johnny Stilou, CFO  
Phone: +45 2960 3532  
E-mail: [jos@scandiononcology.com](mailto:jos@scandiononcology.com)

The information was provided by the contact person above for publication on November 5, 2024, at 17.00 CET.

### About Scandion Oncology

Scandion Oncology (Scandion) is a clinical-stage biotech company using an innovative drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert drug resistance.

Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion's lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer.

Scandion is based in Copenhagen and is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). Vator Securities is the Company's certified advisor on Nasdaq First North Growth Market